Amg9810

Reagents and the concentrations used were selected from previous TPMD literature [3 (link), 11 (link)–14 (link)] and from the TRP channel literature [15 (link)]. Dulbecco’s modified Eagle’s medium (DMEM) and Ca⁺⁺-free Keratinocyte-SFM medium (K-SFM), and alexa fluor 488 dextran (FDx) were purchased from ThermoFisher Scientific, Waltham, MA. Cal-520-AM dye was purchased from AAT Bioquest, Sunnyvale, CA. Cyclopiazonic acid (CPA), 18-α glycyrrhetinic acid (18α-GA), apyrase, AMG 9810, x-methyltryptophan (AMTB) and ryanodine were purchased from Sigma-Aldrich, St. Louis, MO. Thapsigargin was purchased from Abcam, Cambridge, United Kingdom, and N-(4-tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl) tetrahydropyrazine-1(2H)-carbox-amide (BCTC) was purchased from Focus Biomolecules, Plymouth Meeting, PA.

The following chemical reagents were used in this study: AMG9810 (Sigma-Aldrich, St. Louis, MO, USA, A2731), capsaicin (Sigma-Aldrich, M2028), gefitinib (Selleckchem, Houston, TX, USA, S1025), cisplatin (Selleckchem, S1166), spautin-1 (Selleckchem, S78880), and bafilomycin A1 (Sigma-Aldrich, B1793-2UG). The chemical reagents we used were dissolved in below solvents. AMG9810, gefitinib, spautin-1, or bafilomycin A1: Dimethyl sulfoxide (DMSO); cisplatin: Dimethyl formamide (DMF); capsaicin: ethanol.

The TRPA1 antagonist HC030031 (2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-purin-7-yl)-N-(4-isopropyl-phenyl)-acetamide 1) (Tocris, UK) was either dissolved in 10% DMSO in saline and administered i.p. at a dose of 100 mg kg⁻¹ 30 min53 (link) before local cold water immersion or in 8% DMSO, 2% Tween-80 in saline and administered i.v. at a dose of 6 mg kg⁻¹ (ref. 54 (link)) at the peak vasoconstriction phase (0–2 min) following local cold water immersion. The TRPM8 antagonist AMTB (N-(3-aminopropyl)-2-[(3-methylphenyl) methyl]oxy-N-(2-thienylmethyl)benzamide hydrochloride salt) was dissolved in 10% DMSO in saline, TRPV1 antagonist SB366791 (4′-Chloro-3-methoxycinnamanilide) in 2% DMSO in saline or AMG9810 ((2E)-N-(2,3-Dihydro-1,4-benzodioxin-6-yl)-3-[4-(1,1-dimethylethyl)phenyl]-2-propenamide) (Sigma, UK) in 2% DMSO and 5% Tween-80 in saline and administered at a dose of 10 (ref. 55 (link)), 25 (ref. 56 (link)) and 50 mg kg⁻¹ (ref. 57 (link)), respectively. The CGRP receptor antagonists were dissolved as follows: CGRP_8–37 was dissolved in 0.01% bovine serum albumin (BSA) and administered i.v. at 400 nmol kg⁻¹ (ref. 58 (link)) (Tocris,UK). BIBN4096 ((1-piperidinecarboxamide,N-[2-[[5-amino-1-[[4-(4-pyridinyl)-1-piperazinyl]carbonyl]pentyl]amino]-1-[3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-,[R-(R*,S*)]) (Tocris, UK) was dissolved in a minimum volume of 1M HCl (0.5 mg per 50 μl) and the solution was made up to the required final volume with saline at a final stock concentration of 2 mg ml⁻¹, and then titrated with 1 M NaOH to return the pH to neutral. BIBN4096 was administered i.v. at 0.3 mg kg⁻¹ (refs 59 (link), 60 (link)). The NK₁ receptor antagonist SR140333 ((S)1-(2-[3-(3,4-dichlorophnyl)-1-(3-isopropoxyphenylacetyl)piperidin-3-yl]ethyl)-4-phenyl-1-azoniabicyclo[2.2.2]octane chloride)60 (link), a gift from Dr X. Emonds-Alt, Sanofi, Toulouse, France, was dissolved in saline and administered at a dose of 480 nmol kg⁻¹ i.v. The non-selective NOS inhibitor L-NAME60 (link) or the selective nNOS inhibitor SMTC (Sigma, UK) was dissolved in saline and administered i.v. at 15 mg kg⁻¹ (ref. 61 (link)). The cyclooxygenase inhibitor indomethacin (Sigma, UK) was dissolved in 5% NaHCO₃ in saline and administered i.v. at 20 mg kg⁻¹ (ref. 60 (link)). The non-selective α-adrenoceptor antagonist phentolamine62 (link) was dissolved in saline and administered i.v. at a dose of 10 mg kg⁻¹, whilst the sympathetic nerve blocker guanethidine63 (link) (Sigma, UK) was dissolved in saline and administered subcutaneously (s.c.), at a dose of 30 mg kg⁻¹ daily for four consecutive days. The α₂-adrenoceptor antagonist yohimbine hydrochloride, the selective α_2C-adrenoceptor antagonist JP1302 dihydrochloride and the selective Rho-associated protein kinase (ROCK) inhibitor Y27632 (Tocris, UK) were dissolved in saline and administered at a dose of 10 mg kg⁻¹ (i.p.)64 (link), 3 μg kg⁻¹ (s.c.)65 (link) or 5 mg kg⁻¹ (i.p.)66 (link), respectively. The SOD mimetic TEMPOL was dissolved in saline and administered i.v. at a dose of 30 mg kg⁻¹ (ref. 60 (link)), whilst the mitochondria-targeted superoxide scavenger mito-TEMPO was dissolved in saline and administered i.p. at a dose of 10 mg kg⁻¹ (ref. 67 (link)). The capsaicin analogue resiniferatoxin was dissolved in 10% ethanol, 10% Tween-80 in saline and administered s.c. at a dose of 0.3 mg kg⁻¹ for three consecutive days68 (link). These drugs were administered i.v. 5 min, i.p. 30 min and s.c. 60 min before baseline blood flow recording. The doses used were based on previous and preliminary studies.

Active reagents and the concentrations used were selected from previous TPMD literature^{7 (link),35 (link)–37 (link)} and from the TRP channel literature^{38 (link)}. AMG 9810, AMTB, ryanodine, BAPTA-AM, 18-α glycyrrhetinic acid (18α-GA), apyrase and DAPI were purchased from Sigma-Aldrich, St. Louis, MO; thapsigargin, BCTC, and Cal-520-AM dye were purchased from Abcam, Cambridge, United Kingdom, Focus Biomolecules, Plymouth Meeting, PA, and AAT Bioquest, Sunnyvale, CA, respectively. Polyclonal connexin 43 antibody was purchased from Cell Signaling, Danvers, MA; Alexa Fluor 488 was purchased from Fisher, Pittsburgh, PA. Ca⁺⁺-free Keratinocyte-SFM medium (K-SFM) was purchased from ThermoFisher Scientific (Cat. No.: 10725–018), Waltham, MA.